Phibro Animal Health price target lowered to $20 from $27 at Morgan Stanley

Morgan Stanley analyst Erin Wright lowered the firm’s price target on Phibro Animal Health (PAHC) to $20 from $27 and keeps an Equal Weight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.